Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Efficacy of TX-004HR in Postmenopausal Women With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy

NCT02253173 is registered in ClinicalTrials.gov with TherapeuticsMD as lead sponsor.

NCT NCT02253173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02253173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Efficacy of TX-004HR in Postmenopausal Women With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy
Lead sponsor
TherapeuticsMD
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2014
Completion date
October 31, 2015
Enrollment
764 (actual)
Sites
105

Conditions

As the registry lists them; a condition with its own page is linked.

dyspareunia, menopause, painful intercourse, vulvovaginal atrophy